<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675569</url>
  </required_header>
  <id_info>
    <org_study_id>REB14-1670</org_study_id>
    <nct_id>NCT02675569</nct_id>
  </id_info>
  <brief_title>ACCESS HD: Comparing Catheters to Fistulas in Elderly Patients Starting Hemodialysis</brief_title>
  <acronym>ACCESS HD</acronym>
  <official_title>ACCESS HD Pilot: A Randomized Trial Comparing Catheters to Fistulas in Elderly patientS Starting HemoDialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Applied Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot randomized controlled trial (RCT) is multi-center, parallel-arm, and open label.
      It will test the feasibility and safety of randomizing elderly patients with end-stage kidney
      failure starting hemodialysis with a tunneled/non-tunneled catheter to one of the following
      vascular access strategies: (a) attempt at fistula creation (intervention), or (b) continued
      use of a catheter (comparator). A total number of 100 participants will be enrolled in this
      pilot RCT. The rationale for this trial includes: (1) the importance of the intervention
      question related to the choice of vascular access for patients treated with hemodialysis; (2)
      lack of evidence from clinical trials for decision-making in this area (only observational
      studies are available); (3) existing studies which suggest that fistula use is associated
      with better patient outcomes are very prone to selection bias; (4) need for a clinical trial
      comparing the impact of the two most frequently chosen strategies for vascular access
      (catheter and fistula) in the hemodialysis population; and (5) a feasible and safe trial
      design. The results obtained from this pilot RCT will determine the feasibility and safety of
      conducting a large RCT, which will be powered for the primary outcome of all-cause mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: This pilot RCT will help to address challenges related to patient recruitment,
      protocol adherence, safety, and data collection in the hemodialysis population. The primary
      outcome for this pilot RCT is feasibility, which will be measured by patient recruitment and
      protocol adherence. The secondary outcomes include feasibility-related outcomes, safety
      (which will include expected procedure-related outcomes and causes for hospital admissions),
      and other protocol violations.

      Hypothesis: Results obtained from the pilot RCT will provide feasibility and safety data for
      conducting a large RCT, which will establish a better understanding of the clinical outcomes
      associated with the use of fistula versus catheter for vascular access in the hemodialysis
      population.

      Research Method: This is a multicenter, open-label, RCT, and is expected to be conducted over
      36 months. All screened people who meet the eligibility criteria will have the following data
      collected in a minimal dataset: eligibility, age, sex, program/center, height, weight,
      comorbid conditions, and details of any prior treatment for acute or chronic kidney failure
      (e.g., previous peritoneal dialysis, kidney transplant, or hemodialysis). Every consented
      participant will have the following additional data collected at baseline: baseline
      laboratory values, baseline hemodialysis initiation, history of access procedures,
      patient-reported outcome measures (includes data on quality of life and a vascular access
      questionnaire), and grip strength. The pilot RCT will consist of 6 months of site
      preparation, approximately 24 months of participant accrual, and 6 months of additional
      follow-up time for the last randomized participant. An additional 6 months will be used to
      assess the preliminary data, prepare the report of this pilot RCT, and to prepare and submit
      funding applications for the large RCT. Participants in the pilot RCT will be rolled into the
      large RCT, and will therefore be followed for a total of 36 months (3 years) after
      randomization to assess adherence to the trial protocol, assess safety outcomes, and collect
      qualitative data.

      Statistical Analysis Plan: The primary analysis of the pilot RCT will be descriptive. The
      proportion of people meeting each of the feasibility endpoints with accompanying 95%
      confidence intervals will be calculated. Investigators will describe participant
      characteristics and evaluate reasons for protocol violation, as well as calculate rates of
      drop-ins and other events. Interim or subgroup analyses will not be conducted in this pilot
      RCT.

      Expected Procedure-Related Outcomes (Safety Data): As both catheter and fistula treatment
      strategies are standard of care, the procedure-related outcomes are well known. Investigators
      will collect only expected procedure-related outcomes (i.e., events that have a potentially
      causal relationship to the strategy) that occur within 7 days of the execution of any access
      related intervention. These will include hospital admissions and prolongation of
      hospitalization, status changes, bacterial infections, catheter or exit site infections,
      cannulation injury events. In addition, sites will report all incidents of participant death
      that occur during the trial period. Cause of death will be determined by trial site
      investigators, based on a trial-specific list of classifications, and will be adjudicated for
      accuracy by appropriate members of the trial steering committee, who will be blinded to
      treatment arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility; proportion of eligible people who are randomized (at least 25%)</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility; proportion of those randomized to the intervention arm receiving a fistula attempt within 90 days of randomization (at least 80%)</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Descriptive; reasons for exclusion of all screened participants (feasibility)</measure>
    <time_frame>42 months</time_frame>
    <description>Investigators will consider the reasons for exclusion of screened participants (including competing studies).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive; reasons that people decline to participate (feasibility)</measure>
    <time_frame>42 months</time_frame>
    <description>Investigators will consider the reasons that people decline to participate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive; reasons people are considered ineligible for a fistula attempt (feasibility)</measure>
    <time_frame>42 months</time_frame>
    <description>Investigators will consider the reasons that people are considered ineligible for a fistula attempt.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive; reasons for delayed access to fistula surgery (feasibility)</measure>
    <time_frame>42 months</time_frame>
    <description>Investigators will consider the reasons for delayed access to fistula surgery (&gt; 90 days from randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety; expected procedure-related outcomes for both catheter and fistula treatment strategies that occur within 7 days of the execution of any access related intervention</measure>
    <time_frame>7 days</time_frame>
    <description>Investigators will collect information on expected procedure-related outcomes for both catheter and fistula treatment strategies that occur within 7 days of the execution of any access related intervention. Additionally, coordinators will track causes for hospital admissions and prolongation of hospitalization, and sites will report all incidents of participant death that occur during the trial period to identify if outcomes may have resulted from the trial procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drop-ins</measure>
    <time_frame>42 months</time_frame>
    <description>Investigators will collect the number and reasons for drop-ins and drop-outs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of drop-outs</measure>
    <time_frame>42 months</time_frame>
    <description>Investigators will collect the number and reasons for drop-ins and drop-outs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>End-stage Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter is a method of vascular access for hemodialysis. It consists of a long, thin plastic tube and may be either tunnelled or non-tunnelled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fistula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fistula is a type of vascular access strategy for hemodialysis in which a direct connection of an artery to a vein is created. It is intended to provide an access with good blood flow that can last for decades.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter</intervention_name>
    <description>A method of vascular access for hemodialysis that all participants will have in place prior to randomization.</description>
    <arm_group_label>Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fistula</intervention_name>
    <description>A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.</description>
    <arm_group_label>Fistula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients age â‰¥ 55;

          2. Started hemodialysis using a tunnelled, or non-tunnelled catheter for vascular access;

          3. Treated with hemodialysis for 365 days or less at the time of consent (374 days or
             less at the time of randomization);

          4. Clinically and cognitively stable (able to provide consent within 365 days of
             hemodialysis start);

          5. Hemodialysis is the intended modality of treatment;

          6. End-stage (permanent) kidney failure unlikely to recover kidney function according to
             the attending nephrologist;

          7. Eligible for a fistula attempt as determined by the local multidisciplinary access
             team;

          8. Planning to remain in the current dialysis center for at least 6 months.

        Exclusion Criteria:

          1. Started hemodialysis with a fistula or have a patent fistula already in place;

          2. . Has had a prior arteriovenous graft creation;

          3. Imminent transplant planned (within 6 months, must be booked);

          4. Metastatic malignancy or other condition associated with a life expectancy of less
             than 6 months, in the opinion of the attending nephrologist.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Quinn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pietro Ravani, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Jin</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>77072</phone_ext>
    <email>JinD@smh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Gulewich</last_name>
    <phone>403-955-6387</phone>
    <email>Sharon.Gulewich@albertahealthservices.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2R 0X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Quinn</last_name>
      <email>rrquinn@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Gulewich</last_name>
      <email>Sharon.Gulewich@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Rob Quinn</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pietro Ravani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Pauly</last_name>
    </contact>
    <investigator>
      <last_name>Robert Pauly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Miller</last_name>
    </contact>
    <investigator>
      <last_name>Lisa Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial University of Newfoundland</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brendan Barrett</last_name>
    </contact>
    <investigator>
      <last_name>Brendan Barrett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Walsh</last_name>
    </contact>
    <investigator>
      <last_name>Michael Walsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louise Moist</last_name>
    </contact>
    <investigator>
      <last_name>Louise Moist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Swapnil Hiremath</last_name>
    </contact>
    <investigator>
      <last_name>Swapnil Hiremath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humber River Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3M 0B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gihad Nesrallah</last_name>
    </contact>
    <investigator>
      <last_name>Gihad Nesrallah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Oliver</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Oliver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ron Wald</last_name>
    </contact>
    <investigator>
      <last_name>Ron Wald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, Donaldson C. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002 Sep;40(3):611-22.</citation>
    <PMID>12200814</PMID>
  </reference>
  <reference>
    <citation>Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, Culleton BF; Canadian Society of Nephrology Committee for Clinical Practice Guidelines. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol. 2006 Mar;17(3 Suppl 1):S1-27. Review.</citation>
    <PMID>16497879</PMID>
  </reference>
  <reference>
    <citation>Ravani P, Palmer SC, Oliver MJ, Quinn RR, MacRae JM, Tai DJ, Pannu NI, Thomas C, Hemmelgarn BR, Craig JC, Manns B, Tonelli M, Strippoli GF, James MT. Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol. 2013 Feb;24(3):465-73. doi: 10.1681/ASN.2012070643. Epub 2013 Feb 21. Review.</citation>
    <PMID>23431075</PMID>
  </reference>
  <reference>
    <citation>Quinn RR, Laupacis A, Hux JE, Oliver MJ, Austin PC. Predicting the risk of 1-year mortality in incident dialysis patients: accounting for case-mix severity in studies using administrative data. Med Care. 2011 Mar;49(3):257-66. doi: 10.1097/MLR.0b013e318202aa0b.</citation>
    <PMID>21301370</PMID>
  </reference>
  <reference>
    <citation>Tennankore KK, Soroka SD, Kiberd BA. The impact of an &quot;acute dialysis start&quot; on the mortality attributed to the use of central venous catheters: a retrospective cohort study. BMC Nephrol. 2012 Jul 30;13:72. doi: 10.1186/1471-2369-13-72.</citation>
    <PMID>22846341</PMID>
  </reference>
  <reference>
    <citation>Mazonakis E, Stirling C, Booth KL, McClenahan J, Heron N, Geddes CC. The influence of comorbidity on the risk of access-related bacteremia in chronic hemodialysis patients. Hemodial Int. 2009 Jan;13(1):6-10. doi: 10.1111/j.1542-4758.2009.00327.x.</citation>
    <PMID>19210271</PMID>
  </reference>
  <reference>
    <citation>Lok CE, Allon M, Moist L, Oliver MJ, Shah H, Zimmerman D. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). J Am Soc Nephrol. 2006 Nov;17(11):3204-12. Epub 2006 Sep 20.</citation>
    <PMID>16988062</PMID>
  </reference>
  <reference>
    <citation>Quinn RR, Lamping DL, Lok CE, Meyer RA, Hiller JA, Lee J, Richardson EP, Kiss A, Oliver MJ. The Vascular Access Questionnaire: assessing patient-reported views of vascular access. J Vasc Access. 2008 Apr-Jun;9(2):122-8.</citation>
    <PMID>18609528</PMID>
  </reference>
  <reference>
    <citation>Oliver MJ, Verrelli M, Zacharias JM, Blake PG, Garg AX, Johnson JF, Pandeya S, Perl J, Kiss AJ, Quinn RR. Choosing peritoneal dialysis reduces the risk of invasive access interventions. Nephrol Dial Transplant. 2012 Feb;27(2):810-6. doi: 10.1093/ndt/gfr289. Epub 2011 Jun 21.</citation>
    <PMID>21693682</PMID>
  </reference>
  <reference>
    <citation>Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, Kooman J, Martin-Malo A, Pedrini L, Pizzarelli F, Tattersall J, Vennegoor M, Wanner C, ter Wee P, Vanholder R. EBPG on Vascular Access. Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii88-117.</citation>
    <PMID>17507428</PMID>
  </reference>
  <reference>
    <citation>Casey JR, Hanson CS, Winkelmayer WC, Craig JC, Palmer S, Strippoli GF, Tong A. Patients' perspectives on hemodialysis vascular access: a systematic review of qualitative studies. Am J Kidney Dis. 2014 Dec;64(6):937-53. doi: 10.1053/j.ajkd.2014.06.024. Epub 2014 Aug 10. Review.</citation>
    <PMID>25115617</PMID>
  </reference>
  <reference>
    <citation>Detry MA, Lewis RJ. The intention-to-treat principle: how to assess the true effect of choosing a medical treatment. JAMA. 2014 Jul 2;312(1):85-6. doi: 10.1001/jama.2014.7523.</citation>
    <PMID>25058221</PMID>
  </reference>
  <reference>
    <citation>Murea M, James KM, Russell GB, Byrum GV 3rd, Yates JE, Tuttle NS, Bleyer AJ, Burkart JM, Freedman BI. Risk of catheter-related bloodstream infection in elderly patients on hemodialysis. Clin J Am Soc Nephrol. 2014 Apr;9(4):764-70. doi: 10.2215/CJN.07710713. Epub 2014 Mar 20.</citation>
    <PMID>24651074</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Rob Quinn</investigator_full_name>
    <investigator_title>Nephrologist and Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Vascular access</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Kidney failure</keyword>
  <keyword>Catheter</keyword>
  <keyword>Fistula</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

